Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-α converting enzyme (TACE): Discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1′ substituents
- 15 March 2008
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (6), 1958-1962
- https://doi.org/10.1016/j.bmcl.2008.01.120
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Discovery of β-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitorsBioorganic & Medicinal Chemistry Letters, 2008
- Identification of a Selectivity Determinant for Inhibition of Tumor Necrosis Factor-α Converting Enzyme by Comparative ModelingCell Chemical Biology, 2003
- Chapter 16. TNF-α converting enzyme (TACE) as a therapeutic targetAnnual Reports in Medicinal Chemistry, 2003
- Discovery of γ-Lactam Hydroxamic Acids as Selective Inhibitors of Tumor Necrosis Factor α Converting Enzyme: Design, Synthesis, and Structure−Activity RelationshipsJournal of Medicinal Chemistry, 2002
- Tumor necrosis factor-α converting enzymeThe International Journal of Biochemistry & Cell Biology, 2002
- TACE and other ADAM proteases as targets for drug discoveryDrug Discovery Today, 2001
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisThe New England Journal of Medicine, 2000
- Therapeutic Potential and Strategies for Inhibiting Tumor Necrosis Factor-αJournal of Medicinal Chemistry, 1999
- Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion ProteinThe New England Journal of Medicine, 1997
- Tumor Necrosis Factor: Function, Release and ClearanceCritical Reviews™ in Immunology, 1996